Vasculogenic Mimicry Molecular Subtypes for MIBC Prognosis and Immunotherapy

1,489 previously reported vasculogenic mimicry-related genes were analyzed to classify muscle-invasive bladder cancer patients into three molecular subtypes. The study integrated multi-omics data, including bulk transcriptomic, genomic, mass cytometry, spatial transcriptomic, and metabolomic datasets, to validate a 12-gene prognostic model. This research by Luqing Wei, last updated in May 2026, proposes a subtyping system to guide personalized treatment strategies.

Use Cases

• Predicting patient prognosis based on the identified VM, Mixed-VM, and Non-VM molecular subtypes.
• Evaluating potential response to immunotherapy based on tumor mutational burden and immunosuppressive microenvironment features.
• Investigating metabolic reprogramming and cellular plasticity in aggressive cancer subtypes.
• Guiding targeted drug discovery, such as combined MEK inhibitor and immune checkpoint inhibitor therapy.

Strengths

• Analysis is based on a large set of 1,489 vasculogenic mimicry-related genes.
• The prognostic model and subtyping system were validated across multiple independent cohorts and multi-omics data types.
• The dataset is openly available under a CC-BY-4.0 license.

Limitations

• The primary file format is DOCX, which may contain processed results rather than raw, reusable data tables.
• Column-level documentation and sample data are unavailable, making field semantics and data structure unclear.
• Row count and specific data dimensions are unknown, limiting suitability assessment for direct computational analysis.

Provenance

Source

figshare

Collection Method

Integrated analysis of single-cell and bulk RNA sequencing data alongside other multi-omics datasets.

Freshness

Last updated 2026-05-29 06:07:44